SAKK/Pfizer Award

Every two years the Swiss Group for Clinical Cancer Research (SAKK) and Pfizer (Switzerland) AG award a prize for patient-oriented, practical clinical cancer research. The prize is worth CHF 20,000.

Individuals up to 50 years of age who work in clinical cancer research in Switzerland are eligible to apply. Applicants are asked to submit their research work in the form of a scientific paper that has been submitted to or already published in a peer-reviewed journal within the past year. The paper may not be more than a year old at the time of submission deadline and it must include specific proposals for improving the treatment and the therapeutic results that are achievable in cancer patients.


More information will follow soon here.

In collaboration with Pfizer

  • SAKK/Pfizer Award 2019

    The prize was awarded at the Swiss Oncology & Hematology Congress (SOHC) on 27 June 2019.

    Pfizer 2019

    Dr. med. Eva Graf (Pfizer AG), Prof. Dr. med. Walter Weber (University Hospital Basel), Martina Müller (Pfizer AG), Prof. Dr. med. Roger von Moos (SAKK President)